Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

SGT-212

Gene therapy (AAV vector) · Gene replacement · developed by Solid Biosciences

Phase 1 Most advanced trial

SLDB Developer

1 Registered trials

What is SGT-212?

SGT-212 is an adeno-associated virus serotype AAVhu68 gene therapy containing codon-optimized complementary DNA. It is being studied in Friedreich's ataxia, a neurodegenerative disorder.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Gene therapy (AAV vector)
Mechanism: Gene replacement
Therapy area: Neurology
Developer: Solid Biosciences Inc. (SLDB)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07180355	Phase 1	Friedreich's Ataxia (FA)	Recruiting	SLDB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Friedreich's Ataxia (FA)

More from Solid Biosciences

SGT-003 Phase 3 SGT-501 Phase 1

Sources

ClinicalTrials.gov NCT07180355

Updated Oct 3, 2026. Something wrong or missing? Report it on the SLDB page.

Follow SLDB, the company behind SGT-212

See SLDB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SLDB catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z